TuHURA Biosciences, Inc./NV (HURA) shareholders
Close on Nov 18, 2026Market cap $87.31MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vijay Patel | 12,346,430 | 26.70% | 13D (active) | Oct 18, 2024 |
| Highbridge Capital Management, LLC | 6,060,608 | 9.10% | 13G (passive) | Dec 31, 2025 |
| Charles S. Theofilos, M.D | 2,506,321 | 5.90% | 13G (passive) | Oct 18, 2024 |
| Samir Patel | 2,466,377 | 5.80% | 13G (passive) | Oct 18, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HURA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 2,267,901 | 3.56% | $5.31M | +193,673 | 0.00% |
| Northern Trust Corp | 1,621,042 | 2.54% | $3.79M | +1,322,855 | 0.00% |
| BlackRock, Inc. | 690,088 | 1.08% | $1.61M | −1,760,168 | 0.00% |
| Geode Capital Management, LLC | 484,219 | 0.76% | $1.13M | −502,703 | 0.00% |
| Millennium Management LLC | 454,535 | 0.71% | $1.06M | New | 0.00% |
| Aqr Capital Management LLC | 424,600 | 0.67% | $993.56K | −182,568 | 0.00% |
| Vanguard Fiduciary Trust Co | 251,186 | 0.39% | $587.78K | −35,947 | 0.00% |
| Citadel Advisors LLC | 232,319 | 0.36% | $543.63K | New | 0.00% |
| State Street Corp | 188,404 | 0.30% | $440.87K | −324,509 | 0.00% |
| Jane Street Group, LLC | 163,891 | 0.26% | $383.51K | New | 0.00% |
| Apollon Wealth Management, LLC | 156,519 | 0.25% | $366.25K | −1,491 | 0.00% |
| Qube Research & Technologies Ltd | 145,595 | 0.23% | $340.69K | New | 0.00% |
| Morgan Stanley | 143,257 | 0.22% | $335.22K | +119,424 | 0.00% |
| Goldman Sachs Group Inc | 131,768 | 0.21% | $308.34K | +61,522 | 0.00% |
| Bank of New York Mellon Corp | 121,662 | 0.19% | $284.69K | −89,906 | 0.00% |
| XTX Topco Ltd | 100,424 | 0.16% | $234.99K | +88,911 | 0.00% |
| WealthShield Partners, LLC | 91,530 | 0.14% | $214.18K | – | 0.03% |
| Aster Capital Management (DIFC) Ltd | 89,690 | 0.14% | $209.88K | New | 0.04% |
| Captrust Financial Advisors | 88,373 | 0.14% | $206.79K | New | 0.00% |
| Cetera Investment Advisers | 61,620 | 0.10% | $144.19K | −78,624 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 90 | 9M | 14.1% | 24 / 15 | 33 / 21 | 3M | 4M |
| Q1 2026 | 90 | 10M | 14.9% | 31 / 37 | 9 / 5 | 6M | 0M |
| Q4 2025 | 65 | 6M | 10.1% | 7 / 27 | 14 / 12 | 1M | 0M |
| Q3 2025 | 70 | 6M | 9.6% | 25 / 16 | 11 / 5 | 1M | 1M |
| Q2 2025 | 50 | 6M | 10.0% | 28 / 13 | 1 / 4 | 3M | 0M |
| Q1 2025 | 27 | 4M | 5.7% | 4 / 9 | 5 / 4 | 2M | 0M |
| Q4 2024 | 27 | 2M | 3.4% | 27 / 0 | 0 / 0 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
62 funds held HURA in Q1 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of HURA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,740,756 | 2.73% | $4.07M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 447,671 | 0.70% | $1.05M | 0.00% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 219,328 | 0.34% | $495.68K | 0.00% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 206,600 | 0.32% | $466.92K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 163,708 | 0.26% | $383.08K | 0.03% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 76,331 | 0.12% | $172.51K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 59,410 | 0.09% | $134.27K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 42,988 | 0.07% | $97.15K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 40,006 | 0.06% | $90.41K | 0.01% | May 31, 2026 |
| Vanguard Balanced Index Fund | 29,949 | 0.05% | $70.08K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 16,774 | 0.03% | $39.25K | 0.00% | Jun 30, 2026 |
| Small Cap Index Fund | 14,958 | 0.02% | $33.81K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 11,039 | 0.02% | $25.83K | 0.01% | Jun 30, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 7,465 | 0.01% | $17.47K | 0.00% | Jun 30, 2026 |
| Victory Extended Market Index Fund | 5,613 | 0.01% | $12.18K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| James A. Bianco | Chief Executive Officer, Director | 2,098,307 | 3.29% | Nov 18, 2026 |
| Dan Dearborn | Chief Financial Officer | 0 | – | Jan 8, 2026 |
| Robert E. Hoffman | Director | 68,902 | 0.11% | Feb 17, 2026 |
| George K. Ng | Director | 0 | – | Feb 17, 2026 |
| Alan List | Director | 0 | – | Feb 17, 2026 |
| James S. J. Manuso | Director | 0 | – | Feb 17, 2026 |
| Craig Tendler | Director | 0 | – | Feb 17, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| James A. Bianco Chief Executive Officer, Director | Nov 17, 2026 | Gift | −75,000 | – | – | 2,098,307 |
| James A. Bianco Chief Executive Officer, Director | May 28, 2026 | Gift | −150,000 | – | – | 2,173,307 |
| James A. Bianco Chief Executive Officer, Director | Oct 18, 2024 | Award | +2,323,307 | – | – | 2,323,307 |
| Robert E. Hoffman President, CEO, and CFO, Director | Jun 1, 2023 | Award | +59,800 | – | – | 68,902 |
| Dennis M. Brown Chief Scientific Officer | Jan 5, 2023 | Inheritance | +363 | – | – | 5,302 |
| Anthony Scott Praill Chief Financial Officer | Aug 1, 2022 | Award | +240,087 | – | – | 277,273 |
| Robert E. Hoffman President and CEO, Director | Aug 1, 2022 | Award | +400,145 | – | – | 455,145 |
| Dennis M. Brown Chief Scientific Officer | Aug 1, 2022 | Award | +240,087 | – | – | 246,905 |
| Robert E. Hoffman President and CEO, Director | Feb 15, 2022 | Buy | +55,000 | $0.47 | $25.85K | 55,000 |
| Anthony Scott Praill Chief Financial Officer | Dec 8, 2021 | Buy | +28,700 | $0.68 | $19.52K | 37,186 |
| Saiid Zarrabian Head of Strategic Partnerships, Director | Dec 7, 2021 | Buy | +38,109 | $0.64 | $24.39K | 55,500 |
| Saiid Zarrabian Head of Strategic Partnerships, Director | Dec 6, 2021 | Buy | +11,891 | $0.59 | $7.02K | 17,391 |
| Laura L. Johnson Director | Nov 22, 2021 | Buy | +3,000 | $0.74 | $2.22K | 3,000 |
| Anthony Scott Praill Chief Financial Officer | Apr 29, 2021 | Conversion | +938 | – | – | 8,486 |
| Anthony Scott Praill Chief Financial Officer | Apr 29, 2021 | Other | +8 | – | – | 7,548 |
| Dennis M. Brown Chief Scientific Officer | Apr 29, 2021 | Conversion | +750 | – | – | 6,818 |
| Dennis M. Brown Chief Scientific Officer | Apr 29, 2021 | Other | +6 | – | – | 6,068 |
| Robert Joseph Toth Jr Director | Apr 29, 2021 | Other | +3 | – | – | 1,241 |
| Robert Joseph Toth Jr Director | Apr 29, 2021 | Conversion | +325 | – | – | 1,566 |
| Robert Joseph Toth Jr Director | Mar 31, 2021 | Other | +8 | – | – | 1,238 |
| Dennis M. Brown Chief Scientific Officer | Mar 31, 2021 | Other | +17 | – | – | 6,062 |
| Anthony Scott Praill Chief Financial Officer | Mar 31, 2021 | Other | +22 | – | – | 7,540 |
| Robert Joseph Toth Jr Director | Dec 31, 2020 | Other | +8 | – | – | 1,230 |
| Anthony Scott Praill Chief Financial Officer | Dec 31, 2020 | Other | +22 | – | – | 7,518 |
| Dennis M. Brown Chief Scientific Officer | Dec 31, 2020 | Other | +17 | – | – | 6,045 |
| Robert Joseph Toth Jr Director | Sep 30, 2020 | Other | +8 | – | – | 1,222 |
| Anthony Scott Praill Chief Financial Officer | Sep 30, 2020 | Other | +22 | – | – | 7,496 |
| Dennis M. Brown Chief Scientific Officer | Sep 30, 2020 | Other | +17 | – | – | 6,028 |
| Keith Murphy Director | Aug 19, 2020 | Buy | +181,010 | – | – | 181,010 |
| John Liatos SVP, Business Development, Director | Aug 19, 2020 | Buy | +196,750 | – | – | 196,750 |
| Dennis M. Brown Chief Scientific Officer | Jun 30, 2020 | Other | +17 | – | – | 6,011 |
| Anthony Scott Praill Chief Financial Officer | Jun 30, 2020 | Other | +22 | – | – | 7,474 |
| Robert Joseph Toth Jr Director | Jun 30, 2020 | Other | +8 | – | – | 1,214 |
| Lynda Sarah Cranston Director | Jun 30, 2020 | Other | −8 | – | – | 332 |
| John K. Bell Director | Jun 30, 2020 | Other | +29 | – | – | 9,817 |
| Anthony Scott Praill Chief Financial Officer | Mar 31, 2020 | Other | +22 | – | – | 7,452 |
| Robert Joseph Toth Jr Director | Mar 31, 2020 | Other | +8 | – | – | 1,206 |
| John K. Bell Director | Mar 31, 2020 | Other | +29 | – | – | 9,788 |
| Dennis M. Brown Chief Scientific Officer | Mar 31, 2020 | Other | +17 | – | – | 5,994 |
| Lynda Sarah Cranston Director | Mar 31, 2020 | Other | −8 | – | – | 324 |
| Lynda Sarah Cranston Director | Dec 31, 2019 | Other | +8 | – | – | 316 |
| Dennis M. Brown Chief Scientific Officer | Dec 31, 2019 | Other | +17 | – | – | 5,977 |
| John K. Bell Director | Dec 31, 2019 | Other | +29 | – | – | 9,759 |
| Robert Joseph Toth Jr Director | Dec 31, 2019 | Other | +8 | – | – | 1,198 |
| Anthony Scott Praill Chief Financial Officer | Dec 31, 2019 | Other | +22 | – | – | 7,430 |
| Dennis M. Brown Chief Scientific Officer | Dec 27, 2019 | Gift | −7,500 | – | – | 5,960 |
| Lynda Sarah Cranston Director | Sep 30, 2019 | Other | +8 | – | – | 308 |
| Robert Joseph Toth Jr Director | Sep 30, 2019 | Other | +8 | – | – | 1,190 |
| John K. Bell Director | Sep 30, 2019 | Other | +29 | – | – | 9,730 |
| Anthony Scott Praill Chief Financial Officer | Sep 30, 2019 | Other | +22 | – | – | 7,408 |
| Dennis M. Brown Chief Scientific Officer | Sep 30, 2019 | Other | +17 | – | – | 13,460 |
| John K. Bell Director | Sep 13, 2019 | Buy | +35,000 | $0.68 | $23.80K | 35,000 |
| John K. Bell Director | Sep 13, 2019 | Buy | +35,000 | $0.68 | $23.80K | 44,701 |
| Robert Joseph Toth Jr Director | Jun 28, 2019 | Other | +8 | – | – | 1,182 |
| John K. Bell Director | Jun 28, 2019 | Other | +29 | – | – | 9,701 |
| Dennis M. Brown Chief Scientific Officer | Jun 28, 2019 | Other | +17 | – | – | 13,443 |
| Anthony Scott Praill Chief Financial Officer | Jun 28, 2019 | Other | +22 | – | – | 7,386 |
| Lynda Sarah Cranston Director | Jun 28, 2019 | Other | +8 | – | – | 300 |
| Lynda Sarah Cranston Director | Mar 29, 2019 | Other | +71 | $0.49 | $35 | 2,912 |
| John K. Bell Director | Mar 29, 2019 | Other | +282 | $0.49 | $138 | 96,711 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of TuHURA Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 26,659 shares on Aug 26, 2026 over the last 90 days.
Congress trades
3 trades in TuHURA Biosciences reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Laurel Lee FL15 · spouse | Bought | Jul 13, 2025 | $50K–100K | Aug 9, 2025 |
| Laurel Lee FL15 · spouse | Bought | Nov 25, 2024 | $1K–15K | Jan 7, 2025 |
| Laurel Lee FL15 · spouse | Exchanged | Oct 18, 2024 | $100K–250K | Nov 21, 2024 |
See a number that looks wrong?